Loading…

Design, development and pilot testing of 'Quest', a smartphone-based relapse prevention app for patients with alcohol dependence

To design, develop and pilot the 'Quest' app for smartphone-based relapse prevention for patients diagnosed with alcohol dependence syndrome (ADS). Principles of relapse prevention and motivation enhancement were used to develop the Quest App. Four addiction psychiatrists reviewed the app...

Full description

Saved in:
Bibliographic Details
Published in:Asian journal of psychiatry 2023-05, Vol.83, p.103572-103572, Article 103572
Main Authors: Sharma, Abhishek Kumar, Shadakshari, Darshan, Chand, Prabhat, Murthy, Pratima
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To design, develop and pilot the 'Quest' app for smartphone-based relapse prevention for patients diagnosed with alcohol dependence syndrome (ADS). Principles of relapse prevention and motivation enhancement were used to develop the Quest App. Four addiction psychiatrists reviewed the app using the “app evaluation framework”. Thirty patients (> 18 yrs age) diagnosed with ADS, who had an Android smartphone, were fluent in writing and reading English and agreed to use the app regularly for the next three months were enrolled in this study. After initial treatment for intoxication/withdrawal and with written consent, patients in the study group (TAUQ) were requested to download the Quest application from a downloadable installation file. The usability and acceptability of Quest App amongst TAUQ patients was evaluated using the usability section of the mHealth App Usability Questionnaire (MAUQ). The short-term effectiveness at the end of three months was compared between TAUQ and comparison group who received Treatment as Usual (TAU). Both acceptability (65 %) and usability (5.8 out of 7) of the app were high. The patient groups (with or without Quest app) showed a significant reduction in drinking at 30, 60, and 90 days follow-up compared with their baseline number of drinking days. There was no significant difference between the two groups (with or without Quest App) in the median number of lapses and the median number of days of heavy drinking. This is the first attempt to develop a smartphone app and test its feasibility in preventing relapse among patients with ADS in the Indian population. Further validation of the app after incorporating feedback and testing on a larger sample size and multiple languages is required. •Smartphone app may complement traditional clinic care by helping self-management and preventing relapse.•Quest, an android mobile app focused on preventing relapse was designed and developed for the patient with ADS.•The Quest app was reviewed and tested using the standard 'app evaluation model'.•The usability and acceptability of the App was high (65%) among patients with ADS.•No significant differences found between groups (with/without app) for drinking outcomes at the end of 3-month.
ISSN:1876-2018
1876-2026
DOI:10.1016/j.ajp.2023.103572